| Literature DB >> 29185460 |
Stefanie Raab1, Moritz Klingenstein1, Anna Möller2, Anett Illing2, Jelena Tosic3,4,5, Markus Breunig2, Georg Kuales3, Leonhard Linta1, Thomas Seufferlein2, Sebastian J Arnold6,7, Alexander Kleger8, Stefan Liebau9.
Abstract
Pluripotency can be induced in vitro from adult somatic mammalian cells by enforced expression of defined transcription factors regulating and initiating the pluripotency network. Despite the substantial advances over the last decade to improve the efficiency of direct reprogramming, exact mechanisms underlying the conversion into the pluripotent stem cell state are still vaguely understood. Several studies suggested that induced pluripotency follows reversed embryonic development. For somatic cells of mesodermal and endodermal origin that would require the transition through a Primitive streak-like state, which would necessarily require an Eomesodermin (Eomes) expressing intermediate. We analyzed reprogramming in human and mouse cells of mesodermal as well as ectodermal origin by thorough marker gene analyses in combination with genetic reporters, conditional loss of function and stable fate-labeling for the broad primitive streak marker Eomes. We unambiguously demonstrate that induced pluripotency is not dependent on a transient primitive streak-like stage and thus does not represent reversal of mesendodermal development in vivo.Entities:
Mesh:
Substances:
Year: 2017 PMID: 29185460 PMCID: PMC5707390 DOI: 10.1038/s41598-017-15187-x
Source DB: PubMed Journal: Sci Rep ISSN: 2045-2322 Impact factor: 4.379
Figure 1Upregulation of primitive streak and mesendoderm markers during reprogramming of human somatic cells of fibroblast and keratinocyte origin, but absence of EOMES protein. (A) Schematic overview of the reprogramming experiment for the somatic cells of ectodermal –keratinocytes, and mesodermal origin – fibroblasts. (B) Expression patterns of indicated genes during reprogramming of human keratinocytes (upper row) and human fibroblasts (lower row). All mRNA levels are expressed relative to the housekeeping gene HMBS and values have been normalized to iPSCs, which have been set to 1 to illustrate fold induction. (C) Schematic overview of the experimental setup of mesendoderm differentiation. (D) Comparison of marker gene expression for definitive endoderm (CER1) and mesendoderm/primitive streak (LHX1, EOMES) are lower in magnitude for the reprogrammed cells compared to the differentiated cells. (E,F) Protein expression of EOMES and NANOG during the time course of human keratinocytes (E) and human fibroblasts (F) reprogramming. The scale bar represents 100 µm for all images. (G) Western Blot analysis EOMES and NANOG protein expression during reprogramming of fibroblasts. Actin was used as loading control. Lane 1: human foreskin fibroblasts (HFFs) protein lysate, lane 2–6 and 9–15: consecutive days of HFFs reprogramming at indicated time points (d = day), lane 7: fibroblast derived iPSCs, lane 8: mesendodermal differentiation as a positive EOMES control. (H) Mesendodermal differentiation of iPSCs shows a positive signal for EOMES protein.
Figure 2EOMES protein is not detectable during several stages of murine fibroblast reprogramming. (A) Schematic illustration of the Eomes alleles used in (B–H). MEFs carry a GFP knock-in at the Eomes GFP/+ locus (upper and middle panel) allowing for quantification of Eomes GFP/+ positive cells by putative GFP expression[19]. A lentiviral 3-factor (OKS) reprogramming construct includes a tdTomato reporter to track expression of pluripotency markers during reprograming[20]. (B) FACS-based quantification of GFP- and tdTomato-positive cells during reprogramming at the indicated days. GFP-positive cells arise only late, after the reprogramming process indicating differentiation of formed iPSCs (day 21). (C) Corresponding phase contrast images (upper panel) and fluorescence images of the MEF cultures during reprogramming (red, middel panel) and the Eomes GFP/+ reporter signal (green, lower panel). (D) Scheme for spontaneous in vitro differentiation of WT-iPSCs towards embryoid bodies representing early germ layer formation mirrored in the three colors. (E) Comparison of marker gene expression for mesendoderm expression peaks during reprogramming of murine fibroblasts in comparison to iPSCs and cells differentiated in EBs. All mRNA levels are expressed relative to the housekeeping gene Hmbs and values have been normalized to day 10 reprogramming cultures, which have been set to 1 to illustrate fold induction. (F) Scheme for in vitro differentiation of Eomes GFP/+ reporter iPSCs isolated from (A) in embryoid bodies toward mesendoderm using high doses of Activin A. Germ layer formation is mirrored in the three colors, while high doses of Activin A favor endoderm formation (green). (G) Eomes GFP/+ reporter iPSCs are differentiated towards mesendoderm. Expression of GFP validates the functionality of the Eomes GFP/+ reporter. (H) FACS-based quantification of independent experiments from (G).
Figure 3Eomes protein remains absent upon lineage tracing during MEF reprogramming. (A) Schematic illustration of the alleles used in (C,D). In one Eomes allele, the promoter drives a tamoxifen-inducible Cre-recombinase, while the ROSA26-locus harbors a floxed Tom/GFP color switch-reporter. Eomes CreER/+-recombinase activity deletes the tomato leading to GFP activation and a subsequent color switch from red to green[21]. (B) Schematic showing lineage tracing approach to test whether iPSCs pass through an Eomes-positive state. (C) FACS-analysis for SSEA1- and GFP-positive cells at day 18 of reprogramming. Tamoxifen (4-OHT) treatment as indicated. Note that neither condition generates GFP-expressing cells. Representative experiment from n = 2 in triplicates is shown. (D) Upper image: representative image of Eomes CreER/+ROSA26Tom/GFP-iPSCs (isolated from experiments in (C) after 4-OHT treatment) further substantiates data obtained in (C). Lower image: day 5 embryoid body generated from Eomes CreER/+ROSA26Tom/GFP-iPSCs upon 4-OHT and Activin A treatment contains GFP-positive cells. Note that the arising iPSCs from (C) and upper image (D) remain GFP-negative independent of 4-OHT treatment, while 4-OHT and Activin A treatment of established lines induces the expected color switch, indicating specificity of the lineage-tracing allele in vitro. Scale bars in all images: 50 µm.
Figure 4Eomes is dispensable for reprogramming of murine fibroblasts. (A) Schematic illustration of the Eomes alleles used in (D–G). MEFs carry one functional null allele with a GFP knock-in at the Eomes locus and a second conditional allele, where exons 2–5 are flanked by loxP sites. The tamoxifen (4-OHT)-inducible CreER-recombinase is expressed from the Rosa26 locus and used to induce the complete genetic deletion of Eomes by 4-OHT administration[8]. (B,C) 4-OHT treatment regimen used for timed Eomes ablation during reprogramming. Orange lines indicate tamoxifen treatment intervalls: A: d-3 to d-1 (48 h), B: d5–9 (96 h), C: d10-d14 (96 h). (D) Representative images of Alkaline phosphatase staining of iPSC colonies at different timepoints of 4-OHT treatment as indicated. (E,F) FACS-based quantification of (E) Ssea1 and (F) Oct3/4 positive cells at day 20 of reprogramming following with and without 4-OHT administration. Scale bars in all images: 50 µm. Representative experiments from n = 3 in triplicates are shown.